Evaluation of a Retroglandular Oncoplastic Technique as a Standard Level I Oncoplastic Breast-Conserving Surgery: A Retrospective Clinicopathologic Study of 102 Patients With Breast Cancer.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
06 2019
Historique:
received: 20 12 2018
revised: 10 02 2019
accepted: 11 02 2019
pubmed: 18 4 2019
medline: 20 6 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

This study presents a novel Level I oncoplastic breast-conserving surgery technique for performing tumorectomy by retroglandular exploration through a skin incision made in the inferior mammary fold. A retrospective single-center cohort study involving patients with early-stage breast cancer (n = 102) was performed. The patient characteristics were recorded, as well as the quality of life rated by BREAST-Q. Postoperative complications were assessed using the Clavien-Dindo classification system. Esthetic outcomes were evaluated with Breast Cancer Conservative Treatment-cosmetic results (BCCT.core) software and a 5-point Likert scale. The median follow-up time was 11 months (range, 7-25 months). The median specimen weight and operative time were 49.8 g (range, 13.4-117.9 g) and 40 minutes (range, 20-80 minutes), respectively. The mean pathologic tumor size was 15 mm (SD, ±7). Owing to positive surgical margins, re-excisions and mastectomies were performed in 13.7% and 2.9% of patients, respectively. The overall complication rate was 24.5% (n = 25), with the most common being seroma formation (13.7%; n = 14). The median Likert scale score was 4.3 (range, 2.1-5), and the median overall esthetic outcome assessed by BCCT.core was 2.1 points (range, 1-4 points). In BREAST-Q domains, the median scores of the "adverse effects of radiation," "physical well-being," the "satisfaction with breasts," and the "psychosocial well-being" were 27, 35, 90, and 93, respectively. Retroglandular oncoplastic breast-conserving surgery is a novel, effective Level I oncoplastic technique for radical resection of breast tumors ≤ 3 cm in size. Additional advantages include the preservation of natural breast shape, the safety of the technique, and the lack of a need for contralateral symmetrization.

Sections du résumé

BACKGROUND
This study presents a novel Level I oncoplastic breast-conserving surgery technique for performing tumorectomy by retroglandular exploration through a skin incision made in the inferior mammary fold.
PATIENTS AND METHODS
A retrospective single-center cohort study involving patients with early-stage breast cancer (n = 102) was performed. The patient characteristics were recorded, as well as the quality of life rated by BREAST-Q. Postoperative complications were assessed using the Clavien-Dindo classification system. Esthetic outcomes were evaluated with Breast Cancer Conservative Treatment-cosmetic results (BCCT.core) software and a 5-point Likert scale.
RESULTS
The median follow-up time was 11 months (range, 7-25 months). The median specimen weight and operative time were 49.8 g (range, 13.4-117.9 g) and 40 minutes (range, 20-80 minutes), respectively. The mean pathologic tumor size was 15 mm (SD, ±7). Owing to positive surgical margins, re-excisions and mastectomies were performed in 13.7% and 2.9% of patients, respectively. The overall complication rate was 24.5% (n = 25), with the most common being seroma formation (13.7%; n = 14). The median Likert scale score was 4.3 (range, 2.1-5), and the median overall esthetic outcome assessed by BCCT.core was 2.1 points (range, 1-4 points). In BREAST-Q domains, the median scores of the "adverse effects of radiation," "physical well-being," the "satisfaction with breasts," and the "psychosocial well-being" were 27, 35, 90, and 93, respectively.
CONCLUSION
Retroglandular oncoplastic breast-conserving surgery is a novel, effective Level I oncoplastic technique for radical resection of breast tumors ≤ 3 cm in size. Additional advantages include the preservation of natural breast shape, the safety of the technique, and the lack of a need for contralateral symmetrization.

Identifiants

pubmed: 30992191
pii: S1526-8209(18)30884-X
doi: 10.1016/j.clbc.2019.02.005
pii:
doi:

Substances chimiques

Receptors, Estrogen 0
Receptors, Progesterone 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e459-e467

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Zoltán Mátrai (Z)

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.

Mihály Újhelyi (M)

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.

Tibor Kovács (T)

Department of Breast Surgery, Guy's and St Thomas's Hospitals NHS Foundation Trust, London, United Kingdom.

Péter Kelemen (P)

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.

Ákos Sávolt (Á)

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.

Eszter Kovács (E)

Department of Radiological Diagnostics, National Institute of Oncology, Budapest, Hungary.

Klára Éles (K)

Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.

Norbert Mészáros (N)

Department of Radiotherapy, National Institute of Oncology, Budapest, Hungary.

István Kenessey (I)

National Cancer Registry, National Institute of Oncology, Budapest, Hungary.

Alexia Stamatiou (A)

School of Medicine, Semmelweis University, Budapest, Hungary.

Dávid Pukancsik (D)

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary. Electronic address: d.pukancsik@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH